# Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies

## TL;DR

This paper reviews how measuring minimal residual disease helps assess treatment success in multiple myeloma patients using anti-CD38 monoclonal antibodies.

## Contribution

The paper provides updated clinical trial results on anti-CD38 monoclonal antibodies and their impact on MRD in multiple myeloma.

## Key findings

- Anti-CD38 monoclonal antibodies improve response quality in myeloma patients.
- MRD evaluation is becoming routine in clinical practice for multiple myeloma.
- Emerging minimally invasive techniques may complement traditional MRD assessment.

## Abstract

Minimal residual disease (MRD) evaluation is a recognized endpoint in clinical trials. Both next-generation flow and sequencing could be used as complementary techniques to detect myeloma cells after therapy to measure the depth of response and novel drug efficacy. Anti-CD38 monoclonal antibodies combined with proteasome inhibitors and immunomodulatory drugs have increased the quality of response in myeloma patients, and MRD evaluation is also entering routine clinical practice in many hematological centers. This review analyzes updated results from recent clinical trials utilizing anti-CD38 monoclonal antibodies such as isatuximab and daratumumab in terms of their responses and MRD data. MRD-driven therapy appears promising for the future of MM patients, and emerging minimally invasive techniques to assess MRD are under investigation as novel potential methods to replace or integrate traditional MRD evaluation.